Ilaria Lenci

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late

Adriano Pellicelli, Marzia Montalbano, Raffaella Lionetti et al. · Digestive and Liver Disease · 2014 · 103 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C

M. Angélico, A. Petrolati, Raffaella Lionetti et al. · Journal of Hepatology · 2007 · 95 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies

Velia Chiara Di Maio, Valeria Cento, Ilaria Lenci et al. · Liver International · 2017 · 90 citations · Full text

Life Sciences, Infectious Diseases, Clinical Pharmacology +11

A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B

Paola Piccolo, Ilaria Lenci, Luigi Demelia et al. · Antiviral Therapy · 2009 · 88 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence

Ilaria Lenci, Giuseppe Tisone, Daniele Di Paolo et al. · Journal of Hepatology · 2011 · 81 citations · Full text

Medicine, Infectious Diseases, Surgery +17